Tanycytes in Alzheimer's Disease and Frontotemporal Dementia

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age40-85
SponsorUniversity Hospital, Lille

About this trial

Metabolic and hormonal deregulations are both a risk factor and a hallmark of Alzheimer's disease (AD) and frontotemporal dementia (FTD), occurring early in the course of the disease. In FTD in particular, hyperorality and dietary changes are associated with metabolic and hormonal changes such as altered levels of the anorexigenic hormone leptin.

The hypothalamus is a brain region that controls metabolism and hormonal systems. Hypothalamic function depends on its ability to sense peripheral signals. The hypothalamus sits on a circumventricular organ called the median eminence (ME) that puts it in contact with systemic blood circulation. In the ME, fenestrated capillaries allow the diffusion of bloodborne factors. However, despite the lack of blood-brain barrier at brain microvessels, diffusion is controlled by specialized ependymoglial cells, the tanycytes, which exert a barrier function between the ME and the third ventricle and controls the access of blood-borne molecules into the hypothalamus. Previous work from our laboratory and the ERC consortium has highlighted the role of tanycytes not only in the regulation of the release of neurohormones from neuroendocrine nerve terminals into the pituitary portal blood circulation, but also in the transport of circulating leptin into the hypothalamus. Hence hypothalamic dysfunction in AD and FTD can result either from dysregulation of neuroendocrine secretions, direct neuronal loss or from defective transport (and hence resistance) to hormones like leptin.

This study is to demonstrate that leptin transport though tanycytes is early altered in FTD and AD and correlates

Eligibility criteria

Qualifiers

Subjects able to undergo a lumbar puncture

Subjects registered with the French Social Security, in agreement with the French law on biomedical experimentation

absence of cognitive complaint (completion of the memory complaint questionnaire)

absence of significant cognitive impairment: normal MMSE according to age and education levels

Disqualifiers

Subjects with dementia caused by a non-neurodegenerative disease, including patients with severe cerebrovascular risk factor load

Subjects who have contraindications to perform a lumbar puncture

Subjects who have contraindications to perform a MRI scan

Weighted less than 45 kg

Trial design

Treatments tested in this trial

  • Lumbar puncture
  • blood sample

Treatment groups

102 Participants
are divided into 3 treatment groups

Sponsors and collaborators

University Hospital, Lille

Lead sponsor

European Research Council

Collaborator

CH Calais

Collaborator

Centre Hospitalier VALENCIENNES

Collaborator

Région Nord-Pas de Calais, France

Collaborator

Centre Hospitalier de Bethune

Collaborator